Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...
Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...
During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...
(RTTNews) - Vertex, Inc. (VERX) revealed a profit for third quarter that Decreased from last year but beat the Street estimates. The company's bottom line came in at $4.04 million, or $0.02 per share.
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Stoke’s new CEO has a long ...
A Vertex Pharmaceuticals drug viewed as a successor to a non-opioid pill that won a landmark FDA approval earlier this year has failed a mid-stage clinical trial, dealing a setback to the company’s ...
After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...
On this edition of Stock Movers: - Vertex Pharmaceuticals Inc. (VRTX) shares fell after an experimental pain drug failed to provide post-surgery benefits and US regulators said they didn’t see a path ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results